Health
Anti-platelet drug class fails to extend survival in moderately ill COVID-19 patients – News-Medical.Net
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or…
A drug class that blocks the activity of blood platelets and prevents clotting—P2Y12 inhibitors—failed to extend survival or lessen disease severity in patients with COVID-19 who were hospitalized but had a relatively moderate case, a new study finds. All…
Continue Reading
-
Noosa News21 hours agoNew South Wales Blues left to pick up the pieces after fumbling a chance at State of Origin glory
-
Noosa News15 hours agoHelp to make recycling stick
-
Noosa News24 hours agoHow do you choose a safe childcare centre?
-
Noosa News13 hours agoFormer Darling Downs Zoo employee sheds new light on horrific lion attack on teacher Joanne Cabban